Abstract | OBJECTIVE: The goal of this study was to evaluate the effects of the addition of tandospirone, a serotonin-1A (5-HT(1A)) agonist, to ongoing treatment with typical antipsychotic drugs, on two cognitive domains that are relevant to functional outcome in patients with schizophrenia. METHOD: Twenty-six patients with schizophrenia who were receiving stable doses of typical antipsychotics were randomly assigned to adjunctive treatment with 30 mg/day of tandospirone or placebo for 6 weeks. Executive function and verbal memory as well as psychopathology were assessed at baseline and after 6 weeks. RESULTS: Both cognitive measures improved significantly in the patients who received tandospirone; subjects who did not receive tandospirone showed no change. There was no significant change in psychopathology ratings in either group. CONCLUSIONS: The results suggest the usefulness of 5-HT(1A) agonists for enhancing some types of cognitive performance and possibly social and work function in patients with schizophrenia.
|
Authors | T Sumiyoshi, M Matsui, S Nohara, I Yamashita, M Kurachi, C Sumiyoshi, K Jayathilake, H Y Meltzer |
Journal | The American journal of psychiatry
(Am J Psychiatry)
Vol. 158
Issue 10
Pg. 1722-5
(Oct 2001)
ISSN: 0002-953X [Print] United States |
PMID | 11579010
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antipsychotic Agents
- Isoindoles
- Piperazines
- Pyrimidines
- Serotonin Receptor Agonists
- tandospirone
|
Topics |
- Antipsychotic Agents
(therapeutic use)
- Cognition Disorders
(drug therapy)
- Drug Therapy, Combination
- Humans
- Isoindoles
- Piperazines
(therapeutic use)
- Pyrimidines
(therapeutic use)
- Schizophrenia
(drug therapy)
- Schizophrenic Psychology
- Serotonin Receptor Agonists
(therapeutic use)
- Treatment Outcome
|